Results 71 to 80 of about 362,523 (334)

SChLAP1 contributes to non-small cell lung cancer cell progression and immune evasion through regulating the AUF1/PD-L1 axis

Autoimmunity, 2021
SChLAP1 is recently reported as a key oncogenic long non-coding RNA in human cancer. However, whether SChLAP1 functions in non-small cell lung cancer (NSCLC) and its specific potential regulatory mechanism remain unexplored.
Zhonghai Du, Shuxian Niu, Juan Wang, Jun Wu, Sheng Li, Xiuxiu Yi   +5 more
doaj   +1 more source

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma [PDF]

, 2018
Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient ...
Carnero Moya, Amancio, Ferrer, Irene, García Heredia, José Manuel, Molina Pinelo, Sonia, Pérez, Marco, Quintanal Villalonga, Álvaro Diego   +5 more
core   +1 more source

Focus on Nivolumab in NSCLC [PDF]

Frontiers in Medicine, 2016
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L., Canova S., Abbate M., Colonese F., Bidoli P.   +4 more
openaire   +3 more sources

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

FEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel, Caroline Wozniak, Aya Sabri, Ben Haddad, Brooke Lopo, Alvaro Cobos, Sarah Sarofim, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evans   +9 more
wiley   +1 more source

Expression analysis of MINA53: correlation with aberrantly expressed mRNAs and pathological features in non-small lung cancer

Biotechnology & Biotechnological Equipment, 2021
The present study investigated the expression signature of the MINA53 gene in 50 lung adenocarcinoma (LUAD) and 50 squamous cell lung carcinoma (LUSC) tumors and their adjacent non-tumor tissues via RT-qPCR.
Veronika Petkova, Dora Marinova, Silva Kyurkchiyan, Gergana Stancheva, Evgeni Mekov, Darina Kachakova-Yordanova, Yanina Slavova, Dimitar Kostadinov, Vanyo Mitev, Radka Kaneva   +9 more
doaj   +1 more source

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma

Polish Journal of Pathology, 2022
To explore the relationship between PD-L1 expression and gene mutations and survival. PD L1, ALK and MET protein expression were detected by immunohistochemistry, and EGFR gene mutation by RT-PCR in 209 cases of NSCLC.
Kin Chan, Hong Vong, Wai Chu, Kun Cheng, Xue Zhong, Jian Wen   +5 more
doaj   +1 more source

A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells [PDF]

, 2023
Giulia Romano, Patricia Le, Giovanni Nigita, Michela Saviana, Lavender Micalo, Francesca Lovat, Daniel del Valle Morales, Howard Li, Patrick Nana‐Sinkam, Mario Acunzo   +9 more
openalex   +1 more source

eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]

, 2019
CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina, Foulkes, William D., Fu, Zheng, Guiot, Marie-Christine, Huang, Sidong, Kong, Tim, Monast, Anie, Park, Morag, Pelletier, Jerry, Pilon, Virginie, Porco, John A., Sangwan, Veena, Xue, Yibo, Zhu, Xianbing   +13 more
core   +1 more source

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

FEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan, Bethany C. Guerra, Selina Uranga, Jessica M. Cardin, Steven E. Riechman, Mariana Janini Gomes, James D. Fluckey   +6 more
wiley   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source